Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 1, 2005. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity.
- Shares Repurchased: 500,000 Ordinary shares of 25 pence each.
- Repurchase Date: September 1, 2005.
- Price per Share: 1,342.495 pence.
- Treasury Shares Held: 109,123,000 (post-transaction).
- Shares in Issue: 5,835,292,534 (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 500,000 shares for Treasury. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 500,000 share repurchase based on the stated price of 1,342.495 pence.
- Confirm the updated total share count (5,835,292,534 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authority granted.
- Check subsequent Form 20-F filings for the impact of this Treasury share holding on earnings per share calculations.